Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 5/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23594348 | 0.88 | CRBN (0.58) | DDB1CRBN | |
| SCHEMBL26042988 | 0.77 | CRBN (0.41) | DDB1CRBN | |
| SCHEMBL26328764 | 0.74 | DDB1 (0.52) | DDB1CRBN | |
| SCHEMBL25847910 | 0.73 | HTT (0.43) | DDB1CRBN | |
| SCHEMBL25847912 | 0.73 | CRBN (0.50) | DDB1CRBN | |
| SCHEMBL21946664 | 0.70 | CRBN (0.62) | DDB1CRBN | |
| SCHEMBL24890787 | 0.70 | CRBN (0.62) | DDB1CRBN | |
| SCHEMBL26042995 | 0.69 | CRBN (0.40) | DDB1CRBN | |
| SCHEMBL25026925 | 0.68 | CRBN (0.58) | DDB1CRBN | |
| SCHEMBL23594548 | 0.68 | DDB1 (0.58) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230142629-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | GILEAD SCIENCES, INC. | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142629-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | IRAK1, IRAK2, IRAK4 | DDB1 661/4885CRBN 324/4885 |
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, CBL, XIAP | DDB1 778/4885CRBN 117/4885 |
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, CBL, XIAP | DDB1 778/4885CRBN 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.